Efficacy of individualized orelabrutinib-based regimens in relapsed or refractory central nervous system lymphoma

BackgroundRelapsed or refractory central nervous system lymphoma (rrCNSL) lacks established preferred treatment and carries an inferior prognosis. Bruton’s tyrosine kinase inhibitor (BTKi) showed promising effectiveness. Orelabrutinib is a second-generation BTKi with a high concentration in cerebros...

Full description

Bibliographic Details

Published in:	Frontiers in Neurology
Main Authors:	Yuchen Wu, Xuefei Sun, Liwei Lv, Qu Cui, Jun Qian, Ruixian Xing, Xueyan Bai, Yuedan Chen, Qing Liu, Wenyuan Lai, Chunji Gao, Shengjun Sun, Nan Ji, Yuanbo Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Subjects:	central nervous system lymphoma relapsed or refractory Bruton’s tyrosine kinase inhibitor orelabrutinib methotrexate
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2025.1570224/full